A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma

Name: A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
Published: 2026
License: Public Domain

Institute of Hematology & Blood Diseases Hospital, China · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

t-cell acute lymphoblastic leukemia, t-lymphoblastic lymphoma, relapsed/refractory hematologic malignancies, cd5-car-t cell therapy, nano car-t, relapsed refractory t-all, relapsed refractory t-lymphoblastic lymphoma, phase 1/2 clinical trial, hematologic malignancies, interventional, phase1, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma

Related documents